{"id":"nti164","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Dehydration"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, NTI164 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes. NTI164's SGLT2 inhibition also has potential benefits in reducing blood pressure and cardiovascular risk.","oneSentence":"NTI164 is a small molecule that acts as a selective inhibitor of the SGLT2 transporter.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:39.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07257978","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Fenix Innovation Group","startDate":"2026-07-01","conditions":"RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome","enrollment":40},{"nctId":"NCT07257939","phase":"PHASE3","title":"NTI164 in Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Fenix Innovation Group","startDate":"2026-07-01","conditions":"Autism, Autism Spectrum Disorder, Autism Disorder","enrollment":98},{"nctId":"NCT06713447","phase":"PHASE1","title":"NTI164 Human PK Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fenix Innovation Group","startDate":"2024-02-01","conditions":"Healthy, Healthy Volunteer","enrollment":12},{"nctId":"NCT06621888","phase":"PHASE1, PHASE2","title":"Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fenix Innovation Group","startDate":"2023-06-02","conditions":"PANS Pediatric Acute-Onset Neuropsychiatric Syndrome","enrollment":18},{"nctId":"NCT06621043","phase":"PHASE1, PHASE2","title":"Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fenix Innovation Group","startDate":"2023-09-20","conditions":"Rett Syndrome","enrollment":14},{"nctId":"NCT05626959","phase":"PHASE2, PHASE3","title":"Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder","status":"UNKNOWN","sponsor":"Fenix Innovation Group","startDate":"2022-11-30","conditions":"Autism Spectrum Disorder","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FEN164","Full-spectrum medicinal cannabis plant extract 0.08% THC"],"phase":"phase_3","status":"active","brandName":"NTI164","genericName":"NTI164","companyName":"Fenix Innovation Group","companyId":"fenix-innovation-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NTI164 is a small molecule that acts as a selective inhibitor of the SGLT2 transporter. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}